arXiv:2608.13786v1 Announce Type: cross
Abstract: Large language model (LLM) chatbots are increasingly used to answer clinical questions with citations to relevant clinical studies. Prior research has largely focused on citation fabrication, leaving a gap in evaluating the quality of retrieved studies and the factors driving their selection. In this study, we evaluated three general-purpose LLM chatbots: Claude Sonnet 5, Gemini 3.1 Pro, and ChatGPT GPT-5.5. We prompted the models with clinical questions adapted from 20 review questions in Issues 6 and 7 of the 2026 Cochrane Database of Systematic Reviews, simulating patient, clinician, and evidence-synthesis researcher roles. Each chatbot was queried under each user role with four independent repetitions, yielding 720 responses. Each chatbot was asked to support its answers with primary clinical citations, which we benchmarked against the included and excluded study sets of the Cochrane reviews. On average, a chatbot response retrieved 39.2% $\pm$ 29.8% of Cochrane included studies, while citing 5.0% $\pm$ 9.4% of excluded studies. Recall of Cochrane included studies varied significantly by model and user role. ChatGPT achieved higher recall than Claude or Gemini (63.1% $\pm$ 29.5% vs. 37.0% $\pm$ 23.8% vs. 17.3% $\pm$ 13.1%; $p=2.0\times10^{-5}$). The researcher role yielded higher recall than the clinician or patient roles (42.8% $\pm$ 30.8% vs. 38.6% $\pm$ 28.9% vs. 36.1% $\pm$ 29.3%; $p=2.0\times10^{-5}$). Controlling for publication year, citations per year, and open-access status, sample size was the only independently significant predictor of retrieval (odds ratio 1.80 per 1-unit increase in log sample size, 95% CI 1.37-2.36, $p=2.34\times10^{-5}$). These findings suggest that while LLM chatbots can retrieve some studies identified by expert reviewers, their performance varies by model and user role, and they exhibit a bias toward clinical trials with larger sample sizes.
Abstract: Large language model (LLM) chatbots are increasingly used to answer clinical questions with citations to relevant clinical studies. Prior research has largely focused on citation fabrication, leaving a gap in evaluating the quality of retrieved studies and the factors driving their selection. In this study, we evaluated three general-purpose LLM chatbots: Claude Sonnet 5, Gemini 3.1 Pro, and ChatGPT GPT-5.5. We prompted the models with clinical questions adapted from 20 review questions in Issues 6 and 7 of the 2026 Cochrane Database of Systematic Reviews, simulating patient, clinician, and evidence-synthesis researcher roles. Each chatbot was queried under each user role with four independent repetitions, yielding 720 responses. Each chatbot was asked to support its answers with primary clinical citations, which we benchmarked against the included and excluded study sets of the Cochrane reviews. On average, a chatbot response retrieved 39.2% $\pm$ 29.8% of Cochrane included studies, while citing 5.0% $\pm$ 9.4% of excluded studies. Recall of Cochrane included studies varied significantly by model and user role. ChatGPT achieved higher recall than Claude or Gemini (63.1% $\pm$ 29.5% vs. 37.0% $\pm$ 23.8% vs. 17.3% $\pm$ 13.1%; $p=2.0\times10^{-5}$). The researcher role yielded higher recall than the clinician or patient roles (42.8% $\pm$ 30.8% vs. 38.6% $\pm$ 28.9% vs. 36.1% $\pm$ 29.3%; $p=2.0\times10^{-5}$). Controlling for publication year, citations per year, and open-access status, sample size was the only independently significant predictor of retrieval (odds ratio 1.80 per 1-unit increase in log sample size, 95% CI 1.37-2.36, $p=2.34\times10^{-5}$). These findings suggest that while LLM chatbots can retrieve some studies identified by expert reviewers, their performance varies by model and user role, and they exhibit a bias toward clinical trials with larger sample sizes.
This article has been indexed from cs.AI updates on arXiv.org
Read the original article: